___________________
CRISPR/CAS9, a new laboratory tool
The CRISPR/CAS9 technology (Nobel Prize in Chemistry 2020) is revolutionary in the “molecular scissors” category, thanks to its simplicity and low cost of implementation. Guided by its associated RNA, the CAS9 endonuclease specifically cuts the targeted DNA sequence (region of interest). Double-strand breaks are usually resolved by non-homologous end joining (NHEJ), generating indels (knockouts of the targeted gene). By transfecting a template DNA in parallel with the system expressing CAS/guide RNA, the cut DNA can be repaired in a controlled manner by homologous recombination, or even modified (point mutation, myc tag insertion, reporter gene fusion, etc.).
In the laboratory, we have set up the biological tools needed to use this fast-growing technology:
* We use an expression plasmid for the eSpCAS9 protein (high-fidelity CAS9), into which any target sequence can be cloned so that transfected cells synthesize eSpCAS9 and a specific guide RNA: in this way, any gene of interest can be targeted for “cutting”.
* For “controlled” repair with GFP insertion, for example, we construct a template plasmid containing the sequence encoding GFP, flanked by regions homologous to the targeted region (around the CAS9 cut site). An antibiotic resistance gene (Puromycin or Blasticidin) is included in the insert to select edited clones.
Here are two examples of successful insertion of the GFP sequence into the genome of cultured mouse cells, using the CRISPR/CAS9 technique:
Image 1: Skin cells constitutively expressing GFP-Actin-β, which fluoresces the cellular network of filaments.
Image 2: Macrophages producing GFP fluorescent protein after activation of the TNF-α promoter by LPS
This technology is now available in several “non-cutting” variants in which CAS9 is deactivated (dCAS9) and coupled to various effectors, opening up new possibilities for action on genomic DNA (epigenetic modifications, gene activation/inhibition).
_________________
Also to be read
For the 2nd year running, UTCBS is hosting a delegation of South African researchers as part of a bilateral PHC
For the 2nd year running, UTCBS is hosting a delegation of South African researchers as part of a bilateral PHC
CNRS honors Néovacs and UTCBS, united for a therapeutic RNA vaccine against asthma
Suresnes, August 29, 2024 - 8am CET - Neovacs (Euronext Growth Paris : ALNEV), a preclinical-stage biopharmaceutical company developing novel therapies for inflammatory and autoimmune diseases, is honored to be listed among the latest CNRS publications following the...
Publication in Advanced Science of Preclinical tests obtained with a pFAR plasmid
Gene Electrotransfer via Conductivity-Clamped Electric Field Focusing Pivots Sensori-Motor DNA Therapeutics: “A Spoonful of Sugar Helps the Medicine Go Down” https://doi.org/10.1002/advs.202401392
Khair Alareth, Caroline Roques and Nasir Arafath with Nathalie Mignet to present UTCBS’s work at the Controlled release society international congress in Bologna.
UTCBS presents its work at the international congress of the "controlled release society" in Bologna. The UTCBS team has shown the interest of nanoparticles both for the imaging of ROS in vivo and the promotion of antioxydant therapeutic activity. Caroline Roques...